
-
World Rugby unfazed over England dominance of women's game
-
Bruised Real Madrid still defining spirit, personality: Alonso
-
Dolly Parton scraps Vegas shows over health issues
-
Maresca says 'no panic' at Chelsea despite mini-slump
-
FIFPro sounds alarm over 'extreme' conditions at 2026 World Cup
-
Jaguar Land Rover to partly resume output after cyberattack
-
Springboks recall De Jager after Mostert withdraws
-
Alcaraz fights back in Tokyo to emulate Nadal with 10th final of season
-
England bowler Woakes retires from international cricket
-
UK plans tougher rules for migrants seeking to stay in country
-
Jailed Thai ex-PM Thaksin requests royal pardon: lawyer
-
Swiatek says may flout 'crazy' rules to protect health
-
Paris Olympics and Paralympics cost French state 6.6bn euros: audit body
-
Rooney says he has 'no faith' that Amorim can revive Man Utd
-
'Are you watching Donald Trump?': Europe's Ryder Cup golfers taunt president
-
Moldova's pro-EU party hails poll win despite 'dirty' Russian tactics
-
Typhoon Bualoi kills dozens in Vietnam and Philippines
-
Wallabies' big-man Skelton ready to impose himself against All Blacks
-
Robertson wants All Blacks to 'pressure' Wallabies in rematch
-
Sinner cruises into China Open semi-finals as Swiatek moves on
-
GSK switches CEO as Trump tariffs test pharma
-
Trump to push Netanyahu on Gaza peace plan at White House
-
Most markets track Wall St gains after US inflation data
-
Typhoon Bualoi batters Vietnam coast, killing 11
-
Germany's Lufthansa to slash 4,000 jobs by 2030
-
Moldova's pro-EU party wins key polls after Russian meddling claims
-
Mourinho Chelsea return prompts old memories, mixed feelings
-
'Predators': how reality TV explains Epstein obsession
-
Most Asian markets track Wall St higher after US inflation data
-
India, Pakistan trade accusations after Asia Cup trophy debacle
-
Power-packed Australia favourites to rewrite World Cup history
-
Latin artist Bad Bunny to headline Super Bowl half-time show
-
Air France, Airbus back on trial over doomed 2009 Rio flight
-
India's divine designs meld with AI at Durga Puja festival
-
Donald won't rule out Ryder Cup captain return after Europe win
-
Who is Matthieu Blazy, the new man at Chanel?
-
'New chapter': Paris Fashion Week to showcase industry makeover
-
Bradley on US Ryder Cup loss: 'This is no one's fault but mine'
-
Four killed in attack on northern US Mormon church
-
Bradley calls for Ryder Cup rule change for injuries
-
McIlroy slams 'unacceptable' Ryder Cup heckling
-
Embattled Australia telco giant hit by another major outage
-
31 Concept Accelerates Next-Gen DPI Leadership With Strategic Acquisition of Xynthor AI
-
Mahomes leads resurgent Chiefs in Ravens rout, Eagles stay unbeaten
-
Moldova's pro-EU party tops polls hit by Russian meddling claims
-
Europe win emotional Ryder Cup triumph after US fightback
-
Two dead after shooting, fire at US Mormon church
-
Europe must step up efforts to protect environment: report
-
Eagles down Bucs to stay unbeaten, Bills march on
-
Incumbent absent as Cameroon presidential campaigning picks up

Man who let snakes bite him 200 times spurs new antivenom hope
Tim Friede was feeling particularly down on the day after the September 11 attacks, so he went to his basement and let two of the world's deadliest snakes bite him.
Four days later, he woke up from a coma.
"I know what it feels like to die from snakebite," Friede told AFP via video call from his home in the small US town of Two Rivers, Wisconsin.
This experience might put most people off snakes entirely, but Friede simply vowed to be more careful next time.
From 2000 to 2018, he allowed himself to be bitten by snakes more than 200 times. He also injected himself with their venom over 650 times.
Friede endured this pain because he wanted to achieve total immunity to venom, a practice called mithridatism which should not be tried at home.
After a couple of years, Friede started to believe he could be the basis for a better kind of antivenom. The former truck mechanic, who does not have a university degree, long struggled to be taken seriously by scientists.
But last month, a study published in the prestigious Cell journal showed that antibodies from his blood protect against a range of snake venom.
The researchers now hope Friede's hyper-immunity could even lead to the development of a universal antivenom.
This would fill a major need, because currently most antivenoms only cover one or a few of the world's 600 venomous snakes.
Up to 138,000 people are killed by snakebites a year, while 400,000 suffer amputations or other disabilities, according to the World Health Organization.
These figures are believed to be vastly underestimated because snakebite victims typically live in poorer, remote areas.
- 'Pain every time' -
Friede's first bite was from a harmless garter snake when he was five years old.
"I was afraid, I cried, I ran away," said Friede, now 57.
Then he started bringing snakes home and hiding them in pickle jars. His mother sought counselling, but his interest in snakes persisted.
Things escalated after Friede attended a class that taught him how to "milk" snakes for their venom.
How antivenom is made has changed little over the last 125 years.
Small doses of snake venom are injected into animals such as horses, which produce antibodies that can be extracted and used as antivenom.
However this antivenom usually only works for bites from that particular species of snake -- and it includes other antibodies from horse that can cause serious side-effects including anaphylactic shock.
"I thought, well, if they make antivenom in horses, why can't I just use myself as a primate?" Friede said.
He started working through the venom from all the deadly species he could get his hands on, such as cobras, taipans, black mambas and rattlesnakes.
"There is pain every time," he said.
- 'Proud' -
For years, the scientists he contacted to take advantage of his immunity refused to bite.
Then in 2017, immunologist Jacob Glanville, who previously worked on universal vaccines, turned his attention towards antivenom.
Glanville told AFP he had been looking for "a clumsy snake researcher who'd been bit accidentally a couple times," when he came across a video of Friede taking brutal back-to-back snake bites.
When they first spoke, Glanville said he told Friede: "I know this is awkward, but I would love to get my hands on some of your blood."
"I've been waiting for this call for a long time," came the response, Glanville said.
The antivenom described in the Cell paper includes two antibodies from Friede's blood, as well as a drug called varespladib.
It offered mice full protection against 13 of the 19 snake species tested, and partial protection for the remaining six.
The researchers hope a future cocktail will cover far more snakes -- particularly vipers -- with further trials planned on dogs in Australia.
Timothy Jackson of the Australian Venom Research Unit praised the immunological research, but questioned whether a human needed to be involved, pointing to synthetically developed antibodies.
Glanville said the ultimate goal of his US-based firm Centivax was to develop a universal antivenom administered by something like an EpiPen, potentially produced in India to keep the costs down.
Friede said he was "proud" to have made a "small difference" in medical history.
Now working for Centivax, Friede stopped self-inflicting himself with venom in 2018 to save the firm from liability issues.
But he hopes to get bitten by snakes again in the future.
"I do miss it," he said.
O.Schlaepfer--VB